DCLK1, a promising colorectal cancer stem cell marker, regulates tumor progression and invasion through miR-137 and miR-15a dependent manner

被引:16
|
作者
Razi, Sepideh [1 ]
Sadeghi, Asieh [2 ]
Asadi-Lari, Zeynab [3 ]
Tam, Kevin J. [4 ]
Kalantari, Elham [1 ]
Madjd, Zahra [1 ,2 ,5 ]
机构
[1] Iran Univ Med Sci, Oncopathol Res Ctr, Tehran, Iran
[2] Iran Univ Med Sci, Dept Pathol, Tehran, Iran
[3] Univ Toronto, Dept Biol, Toronto, ON, Canada
[4] Univ British Columbia, Vancouver Prostate Ctr, Dept Urol Sci, Vancouver, BC, Canada
[5] Iran Univ Med Sci, Dept Mol Med Adv Technol Med, Tehran, Iran
关键词
Colorectal cancer; Cancer stem cells; DCLK1; MiR-137; miR-15a; EXPRESSION; MICRORNAS; PROLIFERATION; DOUBLECORTIN; INHIBITION; ARREST; GROWTH; CD44;
D O I
10.1007/s10238-020-00665-w
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Cancer stem cells (CSCs) are thought to be a major player in tumor initiation, progression, and metastasis. Targeting CSCs for elimination presents a promising therapeutic strategy; however, this approach will require a stronger understanding of CSC biology and identification of CSC-specific markers. The present study was conducted to examine the correlation between DCLK1 and miR-137 and miR-15a levels in colorectal cancer. A total of 222 samples, including 181 colorectal cancer specimens, 24 adenomatosis, and 17 non-adenomatosis colonic polyps, were stained for DCLK1 expression using immunohistochemistry. Also, expression of miR-137 and miR-15a was assessed in colorectal cancer with high and low DCLK1 expression levels. Most colorectal cancer specimens (76%) showed strong expression of DCLK1, whereas only 21% of adenomatous and none of non-adenomatous colonic polyps showed strong DCLK1 expression. A significant difference in DCLK1 expression was found between colorectal cancer, adenomatous, and non-adenomatous colonic polyps (P < 0.001). Higher expression of DCLK1 was more frequently detected in colorectal cases with larger tumor size (P = 0.03), poor differentiation (P = 0.03), and lymph node involvement (P = 0.04). Comparison of miR-137 and miR-15a in colorectal cancer cases revealed a significant inverse correlation with DCLK1 expression (P = 0.03 andP = 0.04, respectively). DCLK1 may act as a candidate marker for colorectal cancer stem cells. The critical role of DCLK1 in colorectal cancer suggests that it may represent an early diagnostic marker and therapeutic target; however, further investigation is warranted.
引用
收藏
页码:139 / 147
页数:9
相关论文
共 50 条
  • [1] DCLK1, a promising colorectal cancer stem cell marker, regulates tumor progression and invasion through miR-137 and miR-15a dependent manner
    Sepideh Razi
    Asieh Sadeghi
    Zeynab Asadi-Lari
    Kevin J. Tam
    Elham Kalantari
    Zahra Madjd
    Clinical and Experimental Medicine, 2021, 21 : 139 - 147
  • [2] miR-137 Regulates the Tumorigenicity of Colon Cancer Stem Cells through the Inhibition of DCLK1
    Sakaguchi, Masazumi
    Hisamori, Shigeo
    Oshima, Nobu
    Sato, Fumiaki
    Shimono, Yohei
    Sakai, Yoshiharu
    MOLECULAR CANCER RESEARCH, 2016, 14 (04) : 354 - 362
  • [3] DCLK1 plays an important role in colorectal cancer tumorgenesis through the regulation of miR-200c
    Mohammadi, Yasaman
    Tavangar, Seyed Mohammad
    Saidijam, Massoud
    Amini, Razieh
    Etemadi, Katayoon
    Dermani, Fatemeh Karimi
    Najafi, Rezvan
    BIOMEDICINE & PHARMACOTHERAPY, 2018, 103 : 301 - 307
  • [4] Small nucleolar RNA host gene 1 promotes development and progression of colorectal cancer through negative regulation of miR-137
    Fu, Yang
    Yin, Yuhan
    Peng, Sanfei
    Yang, Ge
    Yu, Yang
    Guo, Changqing
    Qin, Yanru
    Zhang, Xiefu
    Xu, Wen
    Qin, Yiyu
    MOLECULAR CARCINOGENESIS, 2019, 58 (11) : 2104 - 2117
  • [5] Overexpression of paxillin induced by miR-137 suppression promotes tumor progression and metastasis in colorectal cancer
    Chen, Dong-Liang
    Wang, De-Shen
    Wu, Wen-Jing
    Zeng, Zhao-Lei
    Luo, Hui-Yan
    Qiu, Miao-Zhen
    Ren, Chao
    Zhang, Dong-Sheng
    Wang, Zhi-Qiang
    Wang, Feng-Hua
    Li, Yu-Hong
    Kang, Tie-Bang
    Xu, Rui-Hua
    CARCINOGENESIS, 2013, 34 (04) : 803 - 811
  • [6] Modified miR-15a has therapeutic potential for improving treatment of advanced stage colorectal cancer through inhibition of BCL2, BMI1, YAP1 and DCLK1
    Fesler, Andrew
    Liu, Hua
    Ju, Jingfang
    ONCOTARGET, 2018, 9 (02) : 2367 - 2383
  • [7] The recently suggested intestinal cancer stem cell marker DCLK1 is an epigenetic biomarker for colorectal cancer
    Vedeld, Hege Marie
    Skotheim, Rolf I.
    Lothe, Ragnhild A.
    Lind, Guro E.
    EPIGENETICS, 2014, 9 (03) : 346 - 350
  • [8] Tuft and Cancer Stem Cell Marker DCLK1: A New Target to Enhance Anti-Tumor Immunity in the Tumor Microenvironment
    Cao, Zhiyun
    Weygant, Nathaniel
    Chandrakesan, Parthasarathy
    Houchen, Courtney W.
    Peng, Jun
    Qu, Dongfeng
    CANCERS, 2020, 12 (12) : 1 - 17
  • [9] Upregulation of circulating cancer stem cell marker, DCLK1 but not Lgr5, in chemoradiotherapy-treated colorectal cancer patients
    Mirzaei, Alireza
    Tavoosidana, Gholamreza
    Modarressi, Mohammad Hossein
    Rad, Afshin Abdi
    Fazeli, Mohammad Sadegh
    Shirkoohi, Reza
    Tavakoli-Yaraki, Masoumeh
    Madjd, Zahra
    TUMOR BIOLOGY, 2015, 36 (06) : 4801 - 4810
  • [10] Dclk1, a tumor stem cell marker, regulates pro-survival signaling and self-renewal of intestinal tumor cells
    Chandrakesan, Parthasarathy
    Yao, Jiannan
    Qu, Dongfeng
    May, Randal
    Weygant, Nathaniel
    Ge, Yang
    Ali, Naushad
    Sureban, Sripathi M.
    Gude, Modhi
    Vega, Kenneth
    Bannerman-Menson, Eddie
    Xia, Lijun
    Bronze, Michael
    An, Guangyu
    Houchen, Courtney W.
    MOLECULAR CANCER, 2017, 16